Raymond James & Associates Ultragenyx Pharmaceutical Inc. Call Options Transaction History
Raymond James & Associates
- $146 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RARE
# of Institutions
286Shares Held
78.6MCall Options Held
570KPut Options Held
228K-
Vanguard Group Inc Valley Forge, PA8.7MShares$356 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY7.09MShares$290 Million5.31% of portfolio
-
Black Rock Inc. New York, NY5.24MShares$214 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA4.1MShares$168 Million0.03% of portfolio
-
Sands Capital Management, LLC Arlington, VA3.86MShares$158 Million0.53% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $2.87B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...